Adolor Corporation to Host Investor Conference Call to Report First Quarter 2010 Financial Results

-- Conference Call Scheduled for April 28, 2010, 8:45 a.m. U.S. EDT --

EXTON, Pa.--(BUSINESS WIRE)-- Adolor Corporation (NasdaqGM:ADLR) today announced that it will hold a conference call at 8:45 a.m. EDT on Wednesday, April 28, 2010, to discuss its first quarter 2010 financial results.

To participate in the audio portion and have the opportunity to pose questions, dial 866-272-9941 for domestic callers or 617-213-8895 for international callers, and enter the passcode 38318251. Investors also can listen to the call live by logging on to the Company’s website at www.adolor.com and clicking on “Investor Insights,” then "Calendar of Events."

A replay of the call will be available beginning approximately two hours after the event. To listen to a replay of the conference call, dial 888-286-8010 (domestic) or 617-801-6888 (international) and enter the passcode 20428470 or listen via Adolor’s website. The replay will be available for one week.

About Adolor Corporation

Adolor Corporation is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products.

Adolor’s first approved product in the United States is ENTEREG® (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is available for short-term use in hospitals registered under the E.A.S.E.™ Program. For more information on ENTEREG, including its full prescribing information, visit www.ENTEREG.com. In collaboration with GlaxoSmithKline (GSK), the Company launched ENTEREG in mid-2008.

The Company’s research and development pipeline includes: two novel delta opioid receptor agonists, currently in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; two opioid receptor antagonists, ADL7445 and ADL 5945, entering development for chronic opioid bowel dysfunction (OBD); and several opioid and non-opioid discovery programs.

For more information, visit www.adolor.com.



CONTACT:

Adolor Corporation
Stephen W. Webster
Senior Vice President, Finance and CFO
484-595-1500

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.